Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 590.00p on 12-01-2026 at 19:10:04
Change 0.00p 0%
Buy 630.00p
Sell 550.00p
Last Trade: Sell 6.00 at 550.00p
Day's Volume: 193
Last Close: 590.00p
Open: 590.00p
ISIN: GB00BMCLYF79
Day's Range 590.00p - 590.00p
52wk Range: 590.00p - 1,250.00p
Market Capitalisation: £91.36m
VWAP: 561.65596p
Shares in Issue: 15.48m

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 6 550.00p SI Trade
13:13:56 - 12-Jan-26
Sell* 27 560.00p Ordinary
12:35:47 - 12-Jan-26
Buy* 8 607.45p Ordinary
08:20:35 - 12-Jan-26
Sell* 152 560.00p Ordinary
08:00:11 - 12-Jan-26
Buy* 470 602.00p Ordinary
14:37:06 - 09-Jan-26
Buy* 340 605.00p Ordinary
14:23:22 - 09-Jan-26
Sell* 1,000 560.00p Ordinary
14:14:39 - 09-Jan-26
Buy* 1 630.00p SI Trade
11:51:55 - 09-Jan-26
Buy* 32 607.45p Ordinary
11:38:46 - 09-Jan-26
Buy* 491 607.45p Ordinary
10:29:05 - 09-Jan-26
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
12th Jan 2026 (Mon) 590.00 590.00 590.00 590.00 193
9th Jan 2026 (Fri) 590.00 590.00 590.00 590.00 2,587
8th Jan 2026 (Thu) 615.00 615.00 590.00 590.00 4,654
7th Jan 2026 (Wed) 615.00 615.00 615.00 615.00 1,665
6th Jan 2026 (Tue) 615.00 615.00 615.00 615.00 1,018
5th Jan 2026 (Mon) 615.00 615.00 615.00 615.00 767
2nd Jan 2026 (Fri) 615.00 615.00 615.00 615.00 0
1st Jan 2026 (Thu) 615.00 615.00 615.00 615.00 0
31st Dec 2025 (Wed) 615.00 615.00 615.00 615.00 4
30th Dec 2025 (Tue) 615.00 615.00 615.00 615.00 3
29th Dec 2025 (Mon) 615.00 615.00 615.00 615.00 1,045
26th Dec 2025 (Fri) 615.00 615.00 615.00 615.00 0
25th Dec 2025 (Thu) 615.00 615.00 615.00 615.00 0
24th Dec 2025 (Wed) 615.00 615.00 615.00 615.00 0
23rd Dec 2025 (Tue) 615.00 615.00 615.00 615.00 546
22nd Dec 2025 (Mon) 650.00 650.00 615.00 615.00 1,834
19th Dec 2025 (Fri) 650.00 650.00 650.00 650.00 21
18th Dec 2025 (Thu) 650.00 650.00 650.00 650.00 0
17th Dec 2025 (Wed) 650.00 650.00 650.00 650.00 61
16th Dec 2025 (Tue) 640.00 650.00 640.00 650.00 7,322
15th Dec 2025 (Mon) 687.50 687.50 640.00 640.00 1,960
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
27th Oct 2025 7:00 am PRN Synthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 2025 11:30 am PRN Result of Extraordinary General Meeting
30th Sep 2025 4:20 pm PRN Director Dealing
29th Sep 2025 7:00 am PRN Half-year Report
22nd Jul 2025 7:00 am PRN Employee Long Term Incentive Plan and Issue of Equity
8th Jul 2025 10:30 am PRN Director Appointment, Board Change
3rd Jul 2025 7:00 am PRN Holding(s) in Company
3rd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
2nd Jul 2025 7:00 am PRN Holding(s) in Company
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

4basebio says "tier one" partner tests vaccine from its template

27th Oct 2025 12:40

(Alliance News) - 4basebio PLC on Monday said its synthetic DNA product has been used in US clinical trials by a "global tier one" pharmaceutical partner. Read More

EARNINGS: Next 15 profit falls; 4basebio and Mollyroe losses widen

1st Oct 2025 12:57

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

20th Jun 2025 12:02

Read More

4basebio expects to sustain DNA sales growth momentum in 2025

27th May 2025 11:57

(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More

IN BRIEF: 4basebio hits "critical milestone" as it secures GMP licence

2nd Apr 2025 09:51

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More

See more 4basebio Plc news
FTSE 100 Latest
Value10,140.70
Change16.10

Login to your account

Forgot Password?

Not Registered